Catalyst Wire Dossier Catalyst Wire Dossier

Bempedoic acid + ezetimibe fixed-dose combination

bempedoic acid + ezetimibe · Esperion Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bempedoic acid + ezetimibe fixed-dose combination, covering 2020-04-09 to 2020-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C [Phase 2]

See pricing